New data presented at ACC 2026 clarifies sotatercept’s role alongside vasodilator-based regimens in PAH patients.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. In this episode, we dive into the early therapies and ...

Pulmonary arterial hypertension, or PAH, is a rare and severe disease characterized by elevated blood pressure in the pulmonary arteries, which transport blood from the heart to the lungs. This can ...

Patients who have heart failure with preserved ejection fraction (HFpEF) and high blood pressure in the lungs (pulmonary ...

A long-term analysis designed by Christian Gerges and Irene Lang at the Department of Medicine II of the University Hospital Vienna and MedUni Vienna indicates that one third of patients with chronic ...

Progressive respiratory failure is the primary cause of death in the coronavirus disease 2019 (Covid-19) pandemic. Despite widespread interest in the pathophysiology of the disease, relatively little ...

Type 2 diabetes and prediabetes can both significantly impact pulmonary health, highlighting the need for early detection and intervention. A new paper has highlighted the significant impact of type 2 ...

Blood vessels in the lungs aren't like the others in the body. This difference becomes clear in pulmonary hypertension, in which only the lungs' blood vessels stiffen progressively, leading to chronic ...

MORRISVILLE, N.C., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, ...

Pulmonary arterial hypertension is characterized by pulmonary vascular remodeling, cellular proliferation, and poor long-term outcomes. Dysfunctional bone morphogenetic protein pathway signaling is ...